BMY : Summary for Bristol-Myers Squibb Company Co - Yahoo Finance

U.S. Markets open in 9 hrs 19 mins

Bristol-Myers Squibb Company (BMY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
54.59+0.31 (+0.57%)
At close: 4:00PM EST
People also watch
MRKLLYABTPFEJNJ
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close54.28
Open54.30
Bid0.00 x
Ask0.00 x
Day's Range54.08 - 54.72
52 Week Range46.01 - 77.12
Volume9,706,078
Avg. Volume12,059,975
Market Cap91.23B
Beta0.89
PE Ratio (TTM)20.60
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.56 (2.86%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Merck, Bristol-Myers, Incyte Race For A Cure In $25 Billion I-O Market
    Investor's Business Daily2 days ago

    Merck, Bristol-Myers, Incyte Race For A Cure In $25 Billion I-O Market

    Merck and Bristol-Myers researchers aren't ready to call immuno-oncology drugs the cure for cancer, but the drugs represent a potential $25 billion market.

  • These Are The First Immune-System Cancer Drugs OK'd By FDA
    Investor's Business Daily2 days ago

    These Are The First Immune-System Cancer Drugs OK'd By FDA

    A handful of products define the new market for drugs that harness the immune system to fight cancer. Here's a list of the drugs and their FDA-approved uses.

  • Reuters3 days ago

    Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook

    Top AstraZeneca shareholder Woodford Investment Management said on Wednesday it had added to its stake in the pharmaceutical firm and was confident in its growth outlook. Woodford, in an update on its website, said shares in AstraZeneca had been unfairly hit since analysts raised concern about the prospects for its key cancer drug trial, Mystic, after rival Bristol-Myers Squibb scaled back its plans in a similar area. Indeed, Bristol-Myers Squibb's problems in this setting may well turn out to be positive for AstraZeneca," Mitchell Fraser-Jones said in a note to investors.